Header Logo

Dusan Stefoski

TitleAssociate Professor, Emeritus/Emerita
InstitutionRush University, Rush Medical College
DepartmentMultiple Sclerosis
Address
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus ID is 6603947979.
    My NIH COMMONS name is DSTEFOSKI.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, di Cantogno EV. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study. Neurodegener Dis Manag. 2023 Oct; 13(5):261-268. PMID: 37535336.
      Citations:    
    2. Osen A, Stefoski D, Shoemaker T, Kaplan T, Morales FS. Cyclophosphamide for severe acute forms of central nervous system inflammatory disorders. J Neurol Sci. 2023 08 15; 451:120693. PMID: 37300950.
      Citations:    
    3. Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, Verdun di Cantogno E. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Mult Scler. 2023 05; 29(6):719-730. PMID: 37012898.
      Citations:    
    4. Graham E, Shoemaker T, Stefoski D, Kontzialis M, Naumaan A, Garg RK. The rare case of a 20-year-old male with rapidly progressive primary angiitis of the CNS with a good outcome. Neurol Neuroimmunol Neuroinflamm. 2020 09; 7(5). PMID: 32518173.
      Citations:    
    5. Gold R, Radue EW, Giovannoni G, Selmaj K, Havrdova EK, Montalban X, Stefoski D, Sprenger T, Robinson RR, Fam S, Smith J, Chalkias S, Giannattasio G, Lima G, Castro-Borrero W. Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. J Neurol. 2020 Oct; 267(10):2851-2864. PMID: 32451615.
      Citations:    
    6. Stefoski D, Balabanov R, Waheed R, Ko M, Koralnik IJ, Sierra Morales F. Treatment of natalizumab-associated PML with filgrastim. Ann Clin Transl Neurol. 2019 May; 6(5):923-931. PMID: 31139690.
      Citations:    
    7. Sierra Morales F, Wright RB, Novo JE, Arvanitis LD, Stefoski D, Koralnik IJ. Glioblastoma in natalizumab-treated multiple sclerosis patients. Ann Clin Transl Neurol. 2017 07; 4(7):512-516. PMID: 28695151.
      Citations:    
    8. Gold R, Radue EW, Giovannoni G, Selmaj K, Havrdova E, Stefoski D, Sprenger T, Montalban X, Cohan S, Umans K, Greenberg SJ, Ozen G, Elkins J. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. BMC Neurol. 2016 Jul 26; 16:117. PMID: 27461166.
      Citations:    
    9. Gold R, Stefoski D, Selmaj K, Havrdova E, Hurst C, Holman J, Tornesi B, Akella S, McCroskery P. Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program. Neurol Ther. 2016 Dec; 5(2):169-182. PMID: 27411694.
      Citations:    
    10. Guo Y, Lennon VA, Popescu BF, Grouse CK, Topel J, Milone M, Lassmann H, Parisi JE, Pittock SJ, Stefoski D, Balabanov R, Lucchinetti CF. Autoimmune aquaporin-4 myopathy in neuromyelitis optica spectrum. JAMA Neurol. 2014 Aug; 71(8):1025-9. PMID: 24911400.
      Citations:    
    11. Tan LA, Kasliwal MK, Muth CC, Stefoski D, Traynelis VC. Is cervical decompression beneficial in patients with coexistent cervical stenosis and multiple sclerosis? J Clin Neurosci. 2014 Dec; 21(12):2189-93. PMID: 25088960.
      Citations:    
    12. Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, McNeill M, Amaravadi L, Sweetser M, Elkins J, O'Neill G. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurol. 2014 May; 13(5):472-81. PMID: 24656609.
      Citations:    
    13. Havrdova E, Giovannoni G, Stefoski D, Forster S, Umans K, Mehta L, Greenberg S, Elkins J. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. Mult Scler. 2014 Apr; 20(4):464-70. PMID: 24022270.
      Citations:    
    14. Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, Stefoski D, Robinson R, Riester K, Rana J, Elkins J, O'Neill G. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013 Jun 22; 381(9884):2167-75. PMID: 23562009.
      Citations:    
    15. Ren Z, Wang Y, Duan T, Patel J, Liggett T, Loda E, Brahma S, Goswami R, Grouse C, Byrne R, Stefoski D, Javed A, Miller SD, Balabanov R. Cross-immunoreactivity between bacterial aquaporin-Z and human aquaporin-4: potential relevance to neuromyelitis optica. J Immunol. 2012 Nov 01; 189(9):4602-11. PMID: 23008451.
      Citations:    
    16. Ko MY, Stefoski D, Balabanov R. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology. 2011 Sep 06; 77(10):1020; author reply 1020. PMID: 21893676.
      Citations:    
    17. Ren Z, Wang Y, Tao D, Liebenson D, Liggett T, Goswami R, Clarke R, Stefoski D, Balabanov R. Overexpression of the dominant-negative form of interferon regulatory factor 1 in oligodendrocytes protects against experimental autoimmune encephalomyelitis. J Neurosci. 2011 Jun 08; 31(23):8329-41. PMID: 21653838.
      Citations:    
    18. Ren Z, Wang Y, Liebenson D, Liggett T, Goswami R, Stefoski D, Balabanov R. IRF-1 signaling in central nervous system glial cells regulates inflammatory demyelination. J Neuroimmunol. 2011 Apr; 233(1-2):147-59. PMID: 21257209.
      Citations:    
    19. Havrdova E, Galetta S, Stefoski D, Comi G. Freedom from disease activity in multiple sclerosis. Neurology. 2010 Apr 27; 74 Suppl 3:S3-7. PMID: 20421571.
      Citations:    
    20. Ren Z, Wang Y, Tao D, Liebenson D, Liggett T, Goswami R, Stefoski D, Balabanov R. Central nervous system expression of interferon regulatory factor 1 regulates experimental autoimmune encephalomyelitis. J Neuroimmune Pharmacol. 2010 Jun; 5(2):260-5. PMID: 20177805.
      Citations:    
    21. Liggett T, Melnikov A, Tilwalli S, Yi Q, Chen H, Replogle C, Feng X, Reder A, Stefoski D, Balabanov R, Levenson V. Methylation patterns of cell-free plasma DNA in relapsing-remitting multiple sclerosis. J Neurol Sci. 2010 Mar 15; 290(1-2):16-21. PMID: 20064646.
      Citations:    
    22. Kaiser CC, Shukla DK, Stebbins GT, Skias DD, Jeffery DR, Stefoski D, Katsamakis G, Feinstein DL. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. J Neuroimmunol. 2009 Jun 25; 211(1-2):124-30. PMID: 19446890.
      Citations:    
    23. Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009 Mar; 8(3):254-60. PMID: 19201654.
      Citations:    
    24. Burt RK, Loh Y, Cohen B, Stefoski D, Stefosky D, Balabanov R, Katsamakis G, Oyama Y, Russell EJ, Stern J, Muraro P, Rose J, Testori A, Bucha J, Jovanovic B, Milanetti F, Storek J, Voltarelli JC, Burns WH. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol. 2009 Mar; 8(3):244-53. PMID: 19186105.
      Citations:    
    25. Loh Y, Oyama Y, Statkute L, Quigley K, Yaung K, Gonda E, Barr W, Jovanovic B, Craig R, Stefoski D, Cohen B, Burt RK. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: role of conditioning regimen used. Blood. 2007 Mar 15; 109(6):2643-548. PMID: 17119125.
      Citations:    
    26. Burt RK, Cohen B, Rose J, Petersen F, Oyama Y, Stefoski D, Katsamakis G, Carrier E, Kozak T, Muraro PA, Martin R, Hintzen R, Slavin S, Karussis D, Haggiag S, Voltarelli JC, Ellison GW, Jovanovic B, Popat U, McGuirk J, Statkute L, Verda L, Haas J, Arnold R. Hematopoietic stem cell transplantation for multiple sclerosis. Arch Neurol. 2005 Jun; 62(6):860-4. PMID: 15956156.
      Citations:    
    27. Burt RK, Cohen BA, Russell E, Spero K, Joshi A, Oyama Y, Karpus WJ, Luo K, Jovanovic B, Traynor A, Karlin K, Stefoski D, Burns WH. Hematopoietic stem cell transplantation for progressive multiple sclerosis: failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood. 2003 Oct 01; 102(7):2373-8. PMID: 12842989.
      Citations:    
    Stefoski's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (135)
    Explore
    _
    Co-Authors (12)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _